N Principi, G Autore, G Ramundo, S Esposito - Viruses, 2023 - mdpi.com
To face the COVID-19 outbreak, a wide range of non-pharmaceutical interventions (NPIs) aimed at limiting the spread of the virus in communities, such as mask-wearing, hand …
C Ernst, D Bejko, L Gaasch, E Hannelas… - …, 2024 - eurosurveillance.org
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84%(1,277 doses/1,524 births) in 2023. That year …
A Pierangeli, R Nenna, M Fracella, C Scagnolari… - Journal of Infection, 2023 - Elsevier
Objectives To scrutinize whether the high circulation of respiratory syncytial virus (RSV) observed in 2021–2022 and 2022–2023 was due to viral diversity, we characterized RSV-A …
A Izu, MC Nunes, F Solomon, V Baillie… - The Lancet Infectious …, 2023 - thelancet.com
Background Non-pharmaceutical interventions affected the circulation of and illness due to endemic respiratory pathogens during the COVID-19 pandemic. We investigated the …
M Redlberger‐Fritz, DN Springer… - Journal of Medical …, 2023 - Wiley Online Library
In 2022, Austria experienced a severe respiratory syncytial virus (RSV) epidemic with an earlier‐than‐usual start (Weeks 35/2021–45/2022) and increased numbers of pediatric …
We report a surge of patients, especially children and adolescents, with respiratory disease caused by Mycoplasma pneumoniae in Denmark since October 2023. While the surge has …
M Ludlow - Current opinion in infectious diseases, 2023 - journals.lww.com
Respiratory syncytial virus infection in the modern era : Current Opinion in Infectious Diseases Respiratory syncytial virus infection in the modern era : Current Opinion in …
OBJECTIVES The 2022 seasonal respiratory syncytial virus (RSV) epidemic in Sydney, Australia saw an unprecedented number of RSV detections. We aimed to characterize …